Teligent Company Profile (NASDAQ:TLGT)

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

Teligent, Inc. (NASDAQ:TLGT) issued its earnings results on Tuesday, August, 8th. The company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.04. The business had revenue of $18.40 million for the quarter, compared to analyst estimates of $20.11 million. Teligent had a positive return on equity of 1.49% and a negative net margin of 11.36%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the company posted $0.02 earnings per share. View Teligent's Earnings History.

3 equities research analysts have issued 12 month price objectives for Teligent's shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Teligent's stock price to reach $9.33 in the next year. View Analyst Ratings for Teligent.

Here are some recent quotes from research analysts about Teligent stock:

• 1. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (10/13/2017)
• 2. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)

Some companies that are related to Teligent include SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL), Aceto Corporation (ACET), Tetraphase Pharmaceuticals (TTPH), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), BioDelivery Sciences International (BDSI), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Evoke Pharma (EVOK) and Juniper Pharmaceuticals (JNP).

Teligent's management team includes the folowing people:

• Jason Grenfell-Gardner, President, Chief Executive Officer, Director
• Jenniffer L. Collins, Chief Financial Officer
• Stephen Richardson, Chief Scientific Officer
• Carole S. Ben-Maimon M.D., Director
• John E. Celentano, Director
• Steven Hubrig Koehler, Director
• Thomas J. Sabatino Jr., Director
• Narendra N. Borkar, Independent Director

Teligent's stock is owned by a number of of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (1.49%). Company insiders that own Teligent stock include James C Gale and Jason Grenfell-Gardner. View Institutional Ownership Trends for Teligent.

Teligent's stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC. Company insiders that have bought Teligent stock in the last two years include James C Gale and Jason Grenfell-Gardner. View Insider Buying and Selling for Teligent.

Shares of Teligent can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teligent stock can currently be purchased for approximately $6.46.